Revista Española de Cardiología - Suplemento - vol 20 ; fasc B ; 2020

42 M. Anguita et al. / Rev Esp Cardiol Supl. 2020; 20(B) :1-46 80. Crespo-Leiro MG, Metra M, Lund LH, et al. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018;20:1505-1535. 81. Xanthakis V, Enserro DM, Larson MG, et al. Prevalence, neurohormonal correlates, and prognosis of heart failure stages in the community. JACC Heart Fail. 2016;4:808-815. 82. Bjork JB, Alton KK, Georgiopoulou VV, Butler J, Kalogeropoulos AP. Defining advanced heart failure: a systematic review of criteria used in clinical trials. J Card Fail. 2016;22:569-577. 83. Fang JC, Ewald GA, Allen LA, et al. Advanced (stage D) heart failure: a statement from the Heart Failure Society of America Guidelines Committee. J Card Fail. 2015;21:519-534. 84. Kernick LA, Hogg KJ, Millerick Y, Murtagh FEM, Djahit A, Johnson M. Does advance care planning in addition to usual care reduce hospitalisation for patients with advanced heart failure: A systematic review and narrative synthesis. Palliat Med. 2018;32:1539-1551. 85. Gheorghiade M, Vaduganathan M, Fonarow GC, Bonow RO. Rehospitalization for heart failure: problems and perspectives. J Am Coll Cardiol. 2013;61: 391-403. 86. Lyons P, Verne J. Pattern of hospital admission in the final year of life. BMJ Support Palliat Care. 2011;1:81. 87. Anguita Sanchez M, Lambert Rodriguez JL, Bover Freire R, et al. Classification and quality standards of heart failure units: scientific consensus of the Spanish Society of Cardiology. Rev Esp Cardiol. 2016;69:940-950. 88. Sica DA, Muntendam P, Myers RL, et al. Subcutaneous furosemide in heart failure: pharmacokinetic characteristics of a newly buffered solution. JACC Basic Transl Sci. 2018;3:25-34. 89. Gilotra NA, Princewill O, Marino B, et al. Efficacy of intravenous furosemide versus a novel, pH-neutral furosemide formulation administered subcutaneously in outpatients with worsening heart failure. JACC Heart Fail. 2018;6:65-70. 90. Sancho-Zamora MA. Home subcutaneous infusion of furosemide in advanced decompensated heart failure. Rev Esp Cardiol. 2014;67:241-242. 91. Zatarain-Nicolas E, Lopez-Diaz J, de la Fuente-Galan L, Garcia-Pardo H, Recio- Platero A, San Roman-Calvar JA. Subcutaneous infusion of furosemide administered by elastomeric pumps for decompensated heart failure treatment: initial experience. Rev Esp Cardiol. 2013;66:1002-1004. 92. Mebazaa A, Parissis J, Porcher R, et al. Short-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensity scoring methods. Intens Care Med. 2011;37:290-301. 93. Chen HH, Anstrom KJ, Givertz MM, et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA. 2013;310:2533-2543. 94. Triposkiadis FK, Butler J, Karayannis G, et al. Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: the Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) trial. Int J Cardiol. 2014;172:115-121. 95. O’Connor CM, Gattis WA, Uretsky BF, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1999;138:78-86. 96. Thorvaldsen T, Benson L, Hagerman I, Dahlstrom U, Edner M, Lund LH. Planned repetitive use of levosimendan for heart failure in cardiology and internal medicine in Sweden. Int J Cardiol. 2014;175:55-61. 97. Packer M, Colucci W, Fisher L, et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail. 2013;1:103-111. 98. Comin-Colet J, Manito N, Segovia-Cubero J, et al. Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial. Eur J Heart Fail. 2018;20:1128-1136. 99. Silvetti S, Nieminen MS. Repeated or intermittent levosimendan treatment in advanced heart failure: An updated meta-analysis. Int J Cardiol. 2016;202:138-143. 100. Silvetti S, Belletti A, Fontana A, Pollesello P. Rehospitalization after intermittent levosimendan treatment in advanced heart failure patients: a meta-analysis of randomized trials. ESC Heart Fail. 2017;4:595-604. 101. Cuffe MS, Califf RM, Adams KF Jr, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287:1541-1547. 102. Felker GM, Benza RL, Chandler AB, et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol. 2003;41:997-1003. 103. Benza RL, Tallaj JA, Felker GM, et al. The impact of arrhythmias in acute heart failure. J Card Fail. 2004;10:279-284. 104. Klein L, O’Connor CM, Leimberger JD, et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation. 2005;111:2454-2460. 105. Klein L, Massie BM, Leimberger JD, et al. Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF). Circ Heart Fail. 2008;1: 25-33. 106. Frohlich GM, Holzmeister J, Hubler M, et al. Prophylactic implantable cardioverter defibrillator treatment in patients with end-stage heart failure awaiting heart transplantation. Heart. 2013;99:1158-1165. 107. Costanzo MR, Guglin ME, Saltzberg MT, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007;49:675-683. 108. Costanzo MR, Negoianu D, Jaski BE, et al. Aquapheresis versus intravenous diuretics and hospitalizations for heart failure. JACC Heart Fail. 2016;4:95-105. 109. Courivaud C, Kazory A, Crepin T, et al. Peritoneal dialysis reduces the number of hospitalization days in heart failure patients refractory to diuretics. Perit Dial Int. 2014;34:100-108. 110. Koch M, Haastert B, Kohnle M, et al. Peritoneal dialysis relieves clinical symptoms and is well tolerated in patients with refractory heart failure and chronic kidney disease. Eur J Heart Fail. 2012;14:530-539. 111. Lu R, Mucino-Bermejo MJ, Ribeiro LC, et al. Peritoneal dialysis in patients with refractory congestive heart failure: a systematic review. Cardiorenal Med. 2015;5:145-156. 112. Nunez J, Gonzalez M, Minana G, et al. Continuous ambulatory peritoneal dialysis as a therapeutic alternative in patients with advanced congestive heart failure. Eur J Heart Fail. 2012;14:540-548. 113. Grodin JL, Carter S, Bart BA, Goldsmith SR, Drazner MH, Tang WHW. Direct comparison of ultrafiltration to pharmacological decongestion in heart failure: a per-protocol analysis of CARRESS-HF. Eur J Heart Fail. 2018;20:1148-1156. 114. Dunbar-Yaffe R, Stitt A, Lee JJ, Mohamed S, Lee DS. Assessing risk and preventing 30-day readmissions in decompensated heart failure: opportunity to intervene? Curr Heart Fail Rep. 2015;12:309-317. 115. Soufer A, Riello RJ, Desai NR, Testani JM, Ahmad T. A blueprint for the post discharge clinic visit after an admission for heart failure. Prog Cardiovasc Dis. 2017;60:237-248. 116. Health Quality O. Effect of early follow-up after hospital discharge on outcomes in patients with heart failure or chronic obstructive pulmonary disease: a systematic review. Ont Health Technol Assess Ser. 2017;17:1-37. 117. Farmakis D, Parissis J, Karavidas A, et al. In-hospital management of acute heart failure: Practical recommendations and future perspectives. Int J Cardiol. 2015;201:231-236. 118. Mebazaa A, Yilmaz MB, Levy P, et al. Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. Eur J Heart Fail. 2015;17:544-558. 119. Dharmarajan K, Hsieh AF, Lin Z, et al. Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. JAMA. 2013;309:355-363. 120. Cowie MR, Lopatin YM, Saldarriaga C, et al. The Optimize Heart Failure Care Program: Initial lessons from global implementation. Int J Cardiol. 2017;236: 340-344. 121. Phelan D, Smyth L, Ryder M, et al. Can we reduce preventable heart failure readmissions in patients enrolled in a Disease Management Programme? Ir J Med Sci. 2009;178:167-171. 122. Hernandez AF, Greiner MA, Fonarow GC, et al. Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure. JAMA. 2010;303:1716-1722. 123. Pacho C, Domingo M, Nunez R, et al. Early postdischarge STOP-HF-Clinic reduces 30-day readmissions in old and frail patients with heart failure. Rev Esp Cardiol. 2017;70:631-638. 124. Consideraciones antes del alta. Paciente hospitalizado por IC. 2019. Disponible en: https://www.fesemi.org/sites/default/files/documentos/publicaciones/ protocolo-manejo-ica.pdf. Consultado 3 Feb 2020. 125. Senni M, Gavazzi A, Oliva F, et al. In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry. Int J Cardiol. 2014;173: 163-169. 126. Franco J, Formiga F, Chivite D, et al. Newonset heart failure—Clinical characteristics and short-term mortality. A RICA (Spanish registry of acute heart failure) study. Eur J Intern Med. 2015;26:357-362. 127. Franco J, Formiga F, Corbella X, et al. De novo acute heart failure: Clinical features and one-year mortality in the Spanish nationwide Registry of Acute Heart Failure. Med Clin (Barc). 2019;152:127-134. 128. Choi KH, Lee GY, Choi JO, et al. Outcomes of de novo and acute decompensated heart failure patients according to ejection fraction. Heart. 2018;104:525-532. 129. Park CS, Park JJ, Mebazaa A, et al. Characteristics, outcomes, and treatment of heart failure with improved ejection fraction. J Am Heart Assoc. 2019;8:e011077. 130. Ho JE, Lyass A, Lee DS, et al. Predictors of new-onset heart failure: differences in preserved versus reduced ejection fraction. Circ Heart Fail. 2013;6:279-286. 131. Greene SJ, Hernandez AF, Dunning A, et al. Hospitalization for recently diagnosed versus worsening chronic heart failure: from the ASCEND-HF trial. J Am Coll Cardiol. 2017;69:3029-3039. 132. Bohm M, Komajda M, Borer JS, et al. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. Eur J Heart Fail. 2018;20:373-381. 133. Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019;380:539-548. 134. Ambrosy AP, Braunwald E, MorrowD, et al. Angiotensin receptorneprilysin inhibition in patients with de novo acute decompensated heart failure: a prespecified subgroup analysis of the PIONEERHF trial. ESC Congress 2019. París, 2019. 135. Senni M, Wachter R, Witte K, et al. Initiation of sacubitril/valsartan in patients with de novo heart failure with reduced ejection fraction: an analysis of the TRANSITION study. Heart Failure 2019-6th World Congress on Acute Heart Failure. Atenas, 2019.